Novavax (NASDAQ:NVAX) is on a recovery trek after collapsing in late 2021. Recently, management said that its latest vaccine version addressing newer Covid-19 subvariants is more effective than older injections.According to a Reuters report, vaccine makers presented animal study data which “showed their 2024-25 shots targeting the JN.1 variant that was dominant earlier this year could neutralize newer subvariants such as KP.2 much better than the older shots.” Novavax and other vaccine developers, including ...